TROP2 as Patient-Tailoring but Not Prognostic Biomarker for Breast Cancer.

"Disclosure Chunhe Wang received compensation from Dartsbio Pharmaceuticals. Otherwise, the authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

"This work was supported by the China National Major Scientific and Technological Special Project for “Significant New Drugs Innovation and Development” (2019ZX09732002-006), the Strategic Priority Research Program of the Chinese Academy of Sciences (CAS) (XDA12020223, XDA12020330), the National Natural Science Foundation of China (81872785 and 81673347), Shanghai Municipal Commission of Science and Technology of China (17431904400, 19YF1457400 and 21S11904500), Institutes for Drug Discovery and Development, Chinese Academy of Sciences (CASIMM0120202007), and Major Scientific and Technological Special Project of Zhongshan City (191022172638719, 210205143867019)."